Breastcancer.org· @Breastcancerorg · X·· 10 小时前评分70
正文 · 原文
New findings from the FOURLIGHT-1 trial presented at #ESMO26 suggest atirmociclib plus Faslodex may help people with HR+, HER2-negative metastatic breast cancer live longer without the cancer growing.
🔗 Read more: https://bit.ly/4ewhPCh
#BreastCancer #BreastCancerResearch #ESMO26 #InsightsbyESMO #ClinicalTrials #Metavivor
34 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
1842O按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.org来源：Breastcancer.org · x.com